TG Therapeutics announced the publication of two journal articles that highlight BRIUMVI in medical journals. One article provided an overview of the evolution of CD20 treatments for multiple sclerosis, offering context for BRIUMVI's place in the therapeutic landscape.
The second publication detailed the experiences of seven individuals with multiple sclerosis who switched to BRIUMVI from other anti-CD20 monoclonal antibody therapies. These patients had previously experienced efficacy or tolerability concerns with their prior treatments.
These publications reinforce the potential for switching patients within the CD20 class and offer anecdotal evidence of BRIUMVI's success in improving patient outcomes. Such scientific validation can support broader adoption among healthcare providers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.